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Endothelial Injury in a Transforming Growth Factor
–Dependent Mouse Model of Scleroderma Induces
Pulmonary Arterial Hypertension
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Objective. To delineate the constitutive pulmo-
nary vascular phenotype of the TRIIk-fib mouse
model of scleroderma, and to selectively induce pulmo-
nary endothelial cell injury using vascular endothelial
growth factor (VEGF) inhibition to develop a model
with features characteristic of pulmonary arterial hy-
pertension (PAH).
Methods. The TRIIk-fib mouse strain ex-
presses a kinase-deficient transforming growth factor 
(TGF) receptor type II driven by a fibroblast-specific
promoter, leading to ligand-dependent up-regulation of
TGF signaling, and replicates key fibrotic features of
scleroderma. Structural, biochemical, and functional
assessments of pulmonary vessels, including in vivo
hemodynamic studies, were performed before and fol-
lowing VEGF inhibition, which induced pulmonary en-
dothelial cell apoptosis. These assessments included bio-
chemical analysis of the TGF and VEGF signaling axes
in tissue sections and explanted smooth muscle cells.
Results. In the TRIIk-fib mouse strain, a con-
stitutive pulmonary vasculopathy with medial thicken-
ing, a perivascular proliferating chronic inflammatory
cell infiltrate, and mildly elevated pulmonary artery
pressure resembled the well-described chronic hypoxia
model of pulmonary hypertension. Following adminis-
tration of SU5416, the pulmonary vascular phenotype
was more florid, with pulmonary arteriolar luminal
obliteration by apoptosis-resistant proliferating endo-
thelial cells. These changes resulted in right ventricular
hypertrophy, confirming hemodynamically significant
PAH. Altered expression of TGF and VEGF ligand and
receptor was consistent with a scleroderma phenotype.
Conclusion. In this study, we replicated key fea-
tures of systemic sclerosis–related PAH in a mouse
model. Our results suggest that pulmonary endothelial
cell injury in a genetically susceptible mouse strain
triggers this complication and support the underlying
role of functional interplay between TGF and VEGF,
which provides insight into the pathogenesis of this
disease.
Pulmonary arterial hypertension (PAH) develops
in up to 10% of patients with systemic sclerosis (SSc;
scleroderma) and is a major cause of mortality (1,2). The
worse outcomes and poorer responses to therapy in
patients with SSc-related PAH compared with idiopathic
PAH suggest that clinical and pathologic differences
exist between different forms of precapillary pulmonary
hypertension (3). In SSc, the timing and frequency of the
development of PAH are consistent with a triggering
event in susceptible individuals (4). The pathologic
hallmark of advanced SSc-related PAH is vascular oblit-
eration with endothelial proliferation, medial hypertro-
phy, and adventitial fibrosis. Endothelial injury and
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apoptosis have been reported, and perivascular inflam-
mation has been observed (5–9).
Dysregulated angiogenesis, with high levels of
circulating vascular endothelial growth factor (VEGF)
and angiostatic factors, is thought to represent an aber-
rant repair mechanism (10,11). These changes are pres-
ent in the arterial circulation of patients with other
forms of PAH, but pulmonary vascular changes may be
more widespread in SSc and involve the pulmonary
venous network (12,13); this may, in part, underlie the
clinical differences in mortality and response to therapy
in SSc-related PAH.
Genetic susceptibility to PAH in patients with
SSc has not yet been clearly shown. Although no asso-
ciation has been observed with the gene encoding bone
morphogenetic protein receptor type II, which underlies
some heritable PAH and idiopathic PAH (14), a role for
altered transforming growth factor  (TGF) superfam-
ily signaling remains possible. Recent studies have re-
vealed polymorphisms in the endoglin gene (an acces-
sory receptor for TGF ligand that has been shown to
be altered in SSc) and KCNA5 in other forms of PAH
(15,16).
In this study, we replicated hallmark features of
PAH by administering the VEGF receptor inhibitor
SU5416 to TRIIk-fib mice, which have previously
been shown to develop several features of human sclero-
derma. We demonstrate a constitutive pulmonary
vascular phenotype reminiscent of the murine chronic
hypoxia model of pulmonary hypertension (PH), includ-
ing changes in medial hypertrophy and raised pulmonary
arterial pressure. We show that administration of
SU5416 induces obliterative endothelial proliferation
characteristic of SSc-related PAH, thus providing insight
into the pathogenesis of SSc-related PAH and generat-
ing a novel mouse model of potential value in preclinical
studies of therapies for this important complication of
SSc.
MATERIALS AND METHODS
Generation of TRIIk-fib–transgenic mice. The gen-
eration of TRIIk-fib–transgenic mice has been described
previously (17,18). Mice were genotyped by polymerase chain
reaction, using primers specific to LacZ and an internal
control. Each experiment was performed by comparing at least
6 mice for each condition and sex-matched littermate controls,
and then the experiments were performed in triplicate. Mice
were ages 6–8 weeks in all of the experiments except the
hemodynamics experiments, in which (for technical reasons)
the mice were ages 12 weeks. Measurements were made by
observers blinded to treatment category or genotype. A 50-
mg/kg intraperitoneal injection of SU5416 (Sigma) in car-
boxymethylcellulose vehicle was administered, as previously
described (19,20). The mice were housed in a clean conven-
tional colony, with access to food and water ad libitum. Strict
adherence to institutional guidelines was practiced, and full
local ethics committee and Home Office approval were ob-
tained prior to all animal procedures.
Long-term exposure to hypoxia. Mice undergoing ex-
posure to hypoxic conditions were housed in a normobaric
hypoxia chamber (850-NBB Nitrogen Dry Box; Plas-Labs) for
3 weeks. Room air balanced with N2 achieved an FiO2 value
of 0.10. CO2-absorbent lime was added to maintain the CO2
content at 1.0%. Gas tension and humidity values were
determined daily to ensure optimal conditions.
Histologic analysis. Lung and cardiac tissue speci-
mens were immersed in 10% formal saline, gluteraldehyde,
RNAlater (Ambion), or liquid nitrogen. Formalin-fixed,
paraffin-embedded sections were stained with hematoxylin
and eosin (H&E), picrosirius red, or elastic–van Gieson for
immunohistochemical analysis, as previously described (21).
The primary antibodies were -galactosidase, CD31, VEGF,
VEGF receptor 1 (VEGFR-1), VEGFR-2, CD3, CD19, and
CD68 (Abcam), TGF1 and p-Smad2/3 (Santa Cruz Biotech-
nology), latency-associated peptide (LAP) TGF1 (R&D Sys-
tems), -smooth muscle actin (Sigma-Aldrich), Ki-67 (Dako),
and cleaved caspase 3 (Cell Signaling Technology). Sections
were viewed and measurements quantified with an Axioskop
Mot Plus microscope using AxioVision software (Zeiss). Ves-
sel thickness was measured using the first 10 consecutive
H&E-stained sections of the right lung, comprising both
proximal and distal vessels in each case. Vessels that had been
sectioned obliquely or longitudinally were not included in the
analysis. Sections used for transmission electron microscopy
were stained with uranyl acetate and Reynold’s lead citrate and
viewed using a Philips 201 transmission electron microscope.
Colocalization was demonstrated by immunostaining, using
multichannel immunofluorescence microscopy.
In vivo measurement of right ventricular systolic pres-
sure (RVSP) and hypertrophy. Hemodynamic measurements
of RVSP and mean arterial blood pressure were obtained in
12-week-old male TRIIk-fib mice and wild-type (WT) lit-
termate mice (20–25 gm). The mice were anesthetized with
1.5% isoflurane and placed in a supine position onto a heating
blanket that was thermostatically controlled at 37°C. First, the
right jugular vein was isolated, and a Millar SPR-671NR
mouse pressure catheter with a diameter of 1.4F was intro-
duced and advanced into the right ventricle to determine
RVSP. Next, mean arterial blood pressure was measured by
isolating the left common carotid artery and introducing a
pressure catheter. Both RVSP and mean arterial blood pres-
sure measurements were recorded into a precalibrated Power-
Lab System (ADInstruments). The mice were killed by isoflu-
rane anesthetic overdose, whole blood samples were collected,
the hearts were removed, and the weights of the right and left
ventricles were recorded.
Quantitative assessment of TGF1 in serum and
bronchoalveolar lavage (BAL) fluid. Total and free murine
TGF1 was quantified in serum and BAL fluid using a
conventional indirect competitive enzyme-linked immunosor-
bent assay according to the manufacturer’s instructions (R&D
Systems). The results were recorded using a Mithras LB 940
Microplate Reader.
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Primary pulmonary artery smooth muscle cell
(PASMC) culture, analysis, and staining. En bloc mouse heart
and lung was microdissected in Hanks’ balanced salt solution.
The pulmonary artery was identified from its origin in the right
ventricle and followed to division and entry into the lungs.
Surrounding fat and connective tissue were stripped, and the
vessel was opened longitudinally. Collagenase digestion was
performed before explanting. After 24 hours, the fetal calf
serum concentration was reduced from 10% to 0.2%. For cell
hypoxia experiments, PASMCs were plated in separate 6-well
plates. The cells were serum-starved and treated with recom-
binant TGF1 (4 ng/ml). One plate was incubated in atmo-
spheric oxygen conditions (labeled 21%), and the paired plate
was incubated inside a modular incubator chamber (Billups-
Rothenburg) containing humidified hypoxic gas (1% O2, 5%
CO2 in nitrogen) for 24 hours. Human PASMCs (PromoCell)
were cultured in standard conditions, as described above,
before lysis for Western blotting.
Cells were seeded for staining in chamber slides (BD
Bioscience), fixed with cold methanol, and permeabilized with
0.2% Triton in phosphate buffered saline before blocking with
isotype-matched serum for 30 minutes. The cells were then
stained for 1 hour with anti–-SMA or anti–-galactosidase
at 1:100 dilution, washed, and incubated with the appropriate
conjugated secondary antibody (Vector BioLabs) before
washing and mounting with Vectastain, and examined with an
Axioskop Z Fluorescence Microscope (Zeiss).
Aortic smooth muscle cell (SMC) culture. The aortae
were dissected, the adventitia stripped, and the vessel opened
longitudinally. After collagenase digestion (1 mg/ml) for 10
minutes at 37°C to remove the endothelium, the remaining
SMCs were grown by explant culture as described above for
PASMCs.
RNA quantitation and analysis. Total RNA was ex-
tracted, quantified, and subjected to quantitative reverse
transcription–polymerase chain reaction analysis, as described
previously (22). The minimum 260:280 ratio was 1.88. RNA
integrity values ranged from 9.1 to 10. The reference genes
Sdha, Rpl13, ActB, and Ubc were used to compute a normal-
ization factor (23). The primer sequences for the genes of
interest were as follows: for mouse Vegf, forward 5-CATCT-
TCAAGCCGTCCTGTGT-3 and reverse 5-CTCCAGGGC-
TTCATCGTTACA-3 (assay efficiency 0.92; R2  0.990); for
mouse Vegfr-a, forward 5-ACTGGACCCTGGCTTTACT-
G-3 and reverse 5-TCTGCTCTCCTTCTGTCGTG-3 (assay
efficiency 0.90; R2  0.999).
Western blotting. Human PASMCs were lysed, ho-
mogenized with radioimmunoprecipitation assay buffer
(Sigma), and stored at 70°C. Protein was fractionated by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
using Tris glycine gels (Invitrogen) with a reference ladder
(SeeBlue Plus; Invitrogen), at 125V for 1.5–2 hours in Tris/
glycine running buffer (Bio-Rad), according to departmental
protocols, and electroblotted to nitrocellulose membranes
(Hybond-C; Amersham). Nonspecific binding was blocked by
membrane incubation with 5% nonfat dry milk in Tris buffered
saline–0.1% Tween 20 (Sigma) and incubated with a 1:1,000
dilution of primary antibodies (VEGF, VEGFR-1, and
VEGFR-2; Abcam). Blots were then developed by incubation
with biotinylated anti-rabbit or anti-mouse antibodies (1:1,000;
Vector BioLabs) as secondary antibodies, followed by incuba-
tion with Vectastain ABC reagent (Vector BioLabs). Signal
was detected using an Amersham ECL luminescence detection
kit followed by exposure to photographic film (Hyperfilm
ECL; Amersham). Densitometry was performed using Mikro
Win 2000 software.
Statistical analysis. Except where indicated otherwise,
data are presented as the mean  SEM of n observations.
Statistical analysis was performed using Student’s t-test or
analysis of variance with post hoc correction for pairwise
comparisons, using Minitab software. P values less than 0.05
were considered significant.
RESULTS
Development of features characteristic of pulmo-
nary vascular disease in TRIIk-fib–transgenic mice.
In addition to the development of interstitial fibrosis in
a minority of mice at 16 weeks of age (21), TRIIk-fib
mice consistently develop a structural pulmonary vascu-
lopathy, as shown in Figure 1. H&E staining of the
pulmonary vasculature at low (Figure 1A) and high
(Figure 1B) power showed medial thickening and a
perivascular inflammatory cell infiltrate (Figure 1A),
with increased deposition of extracellular matrix around
vascular structures. Picrosirius red staining confirmed
increased perivascular collagen deposition, and elastic–
van Gieson staining revealed some architectural disrup-
tion of elastin in the larger pulmonary artery vessels
(Figures 1C and D). Immunostaining with -SMA was
localized to the smooth muscle layer (Figure 1E).
Quantification of inflammatory cellular infil-
trates and pulmonary vessel wall thickening was per-
formed. Cell counts performed on high-power field
(hpf) images containing a central pulmonary vessel
showed higher cell numbers in transgenic mice (mean 
SEM 176  9 nuclei/hpf in transgenic mice and 129  9
nuclei/hpf in WT mice; P 0.008). Immunophenotyping
confirmed a proliferating (Ki-67 positive) chronic in-
flammatory infiltrate containing CD3 and CD19
lymphocytes and CD68 macrophages (Figure 1F).
Vessel wall thickness was expressed as a ratio to
the internal circumference of each vessel. Transgenic
mice had thicker vessel walls overall, but particularly in
the smaller arterioles (diameter 30–60 m) (Figure 1G).
Examination of -SMA–immunostained samples con-
firmed that the increased vessel wall diameter in trans-
genic mice was attributable to increased thickness of the
vascular SMC layer (mean  SEM ratios 0.21  0.01 in
transgenic mice and 0.14 0.01 in WT mice; P 0.001).
Lung tissue from transgenic mice also showed muscular-
ization in very small vessels, with a mean  SEM of
3.0  0.99 vessels of 20 m in diameter/hpf containing
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-SMA compared with 1.8  0.93 of such vessels in
tissue from WT mice (P  0.05) (Figure 1H). Other
hallmark features of advanced SSc-related PAH, such as
intravascular thrombus or plexiform lesions, were not
observed. No features suggestive of endothelial prolifer-
ation or apoptosis were evident. An examination of
endothelial ultrastructure by transmission electron mi-
croscopy showed no evidence of endothelial membrane
abnormalities (data not shown), in contrast to the alve-
olar epithelium in the same model (21).
A modest elevation of RVSP was consistently
observed in the transgenic mouse strain compared with
their WT littermates (for transgenic mice, mean  SEM
24.4 2.6 mm Hg; for WT mice, 18.1 1.3 mm Hg; P
0.05). There was no difference in the RV mass index
(Fulton index) between transgenic and WT mice.
Alteration of TGF expression and signaling
within the pulmonary vasculature of TRIIk-fib mice.
Consistent with the phenotype of up-regulated TGF
signaling in fibroblasts and increased TGF bioactivity,
immunostaining for LAP TGF1 and TGF1 was in-
creased in the perivascular adventitia of transgenic mice
(Figures 2A and B). In transgenic mice, nuclear trans-
location of p-Smad2/3 was increased in the pulmonary
vessels in both the adventitial and smooth muscle layers
(Figure 2C). BAL fluid from transgenic mice contained
higher total TGF compared with that from WT mice
(Figure 2D), despite normal serum TGF levels (data
Figure 1. TRIIk-fib–transgenic mice develop characteristic features of pulmonary vascular disease. A–E, Representative pulmonary arteriole
sections from transgenic and wild-type mice, stained with hematoxylin and eosin (H&E) (A and B), picrosirius red (C), elastic–van Gieson (EVG)
(D), and -smooth muscle actin (-SMA) (E). F, Immunohistochemical staining of perivascular infiltrate for T cells, B cells, and macrophages from
transgenic mice (arrowheads). G, Pulmonary vessel wall thickness:circumference ratios in wild-type and transgenic mice. Bars show the mean 
SEM of 1,000 pulmonary vessels.   P  0.01. H, Muscularization of very small pulmonary vessels in the TRIIk-fib mouse strain (arrowhead).
Original magnification  10 in A;  20 in B–E;  20 in F;  40 in H.
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not shown). These findings suggested that the increased
TGF bioavailability and up-regulation of canonical
TGF signaling in the skin and lungs of transgenic mice
also have effects on vascular SMCs that do not express
the transgene. The same findings were observed within
the aortic SMCs, as previously reported (22).
Pulmonary vascular responses to hypoxia in
TRIIk-fib mice. Based on the findings described
above, WT and transgenic mice were exposed to hypoxic
conditions for 3 weeks and compared with sex-matched
littermates kept in room air. These groups were identi-
fied as transgenic hypoxic, WT hypoxic, transgenic nor-
Figure 2. Transforming growth factor  (TGF) axis signaling is altered within the pulmonary vasculature of TRIIk-fib mice. A–C,
Representative images showing latency-associated peptide (LAP) transforming growth factor 1 (TGF1), TGF1, and p-Smad2/3 immunostaining
of pulmonary arteriole sections from transgenic and wild-type mice. Boxed area shows IgG control. Arrowheads indicate areas of positive staining.
Original magnification  20. D, Total TGF levels in the bronchoalveolar lavage fluid of transgenic mice and their wild-type littermates. Bars show
the mean  SEM.   P  0.01.
Figure 3. Pulmonary vascular response to hypoxia in the TRIIk-fib mouse strain. A, Representative images of hematoxylin and eosin–stained
pulmonary vascular wall sections from wild-type (WT) and transgenic (TG) mice exposed to hypoxia and control mice exposed to normoxic
conditions. Original magnification  20. B, Vessel wall thickness:circumference ratio in WT and transgenic mice before and after exposure to
hypoxia. Bars show the mean  SEM.   P  0.05;   P  0.01.
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moxic, and WT normoxic. All hypoxic mice lost weight
initially, which was regained by 3 weeks, indicating that
hypoxia was tolerated well.
The increased thickness:circumference ratio of
pulmonary arterioles seen in the transgenic normoxic
group was not further exacerbated by hypoxia; hypoxia
consistently increased the thickness:circumference ratio
compared with normoxia in WT mice (Figure 3B).
Hence, the transgenic normoxic mice had vessel wall
thickness comparable with that in the WT hypoxic group
but were refractory to further medial changes (Figure
3A). Following this period of hypoxia, some mice were
returned to normoxic conditions for 4 weeks. The SMC
changes present in WT hypoxic mice resolved, and no
further histologic change was observed in the transgenic
mice. These data suggested that although the constitu-
tive pulmonary vascular phenotype of the TRIIk-fib
mouse strain replicates some of the structural features of
hypoxic PH in WT mice, it is a persistent phenotype that
is not further altered by hypoxia, unlike the reversible
structural and hemodynamic hypoxic phenotype seen in
WT mice.
Systemic VEGFR inhibition–induced prolifera-
tive pulmonary vasculopathy in TRIIk-fib mice. The
results of previous studies suggest that endothelial injury
using the small molecule tyrosine kinase inhibitor
SU5416 may induce obliterative pulmonary vasculopa-
thy in rodents after long-term exposure to hypoxia
(19,20). Given the structural and hemodynamic similar-
ities between the constitutive TRIIk-fib mouse pul-
monary vascular phenotype and the chronic hypoxia
model, including medial hypertrophy without endothe-
lial change and raised pulmonary artery pressure, we
induced endothelial injury by administering SU5416 to
TRIIk-fib mice. A single intraperitoneal injection
of SU5416 was sufficient to induce typical pathologic
changes, without exposure to an hypoxic environment.
Adult mice ages 6 weeks were used for this experiment
Figure 4. Systemic vascular endothelial growth factor receptor inhibition causes pulmonary arterial hypertension in TRIIk-fib mice. A,
Representative images of hematoxylin and eosin–stained pulmonary arteriole sections from transgenic (TG) and wild-type (WT) mice treated with
SU5416 (S) or left untreated. Arrowheads indicate areas of endothelial proliferation. Original magnification 20. B and C, Right ventricular systolic
pressure (RVSP) (B) and RV mass index (C) in WT and transgenic mice following treatment with SU5416. Bars show the mean  SEM of 3
independent replicate experiments.   P  0.05;   P  0.01. LV  left ventricular.
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to avoid conflicting results due to the development of
spontaneous lung fibrosis, which occurs in some
TRIIk-fib mice after age 16 weeks.
H&E staining showed widespread luminal cell
proliferation with obliteration of some small and
medium-sized vessels (Figure 4A). Overall, 39.7% of
vessels were obliterated in transgenic mice, with none
obliterated in the WT mice treated with SU5416 or
vehicle alone, although minor degrees of cellular prolif-
eration arising from the endothelium were seen in WT
mice treated with SU5416 (Figure 4A). Sirius red stain-
ing revealed no exaggerated fibrosis in any group 21 days
after SU5416 treatment, and CD31 immunostaining
confirmed that the luminal cell proliferation observed in
transgenic mice was derived from the endothelium (data
not shown).
RVSP was elevated in transgenic mice following
treatment with SU5416 (Figure 4B). Moreover, the RV
mass index was also increased, suggesting RV hypertro-
phy in treated transgenic mice (Figure 4C). This con-
firms that the elevation in RVSP had hemodynamic
significance not present constitutively in transgenic
mice. VEGF inhibition in the TRIIk-fib mouse strain
consistently induced hemodynamically significant PAH,
leading to RV hypertrophy.
Endothelial cell apoptosis and proliferation in
the lungs following SU5416 treatment. To further inves-
tigate the mechanism for this PAH phenotype, we
Figure 5. SU5416-induced endothelial cell apoptosis and proliferation in the pulmonary vessels of TRIIk-fib mice. A, Representative images
showing cleaved caspase 3 and Ki-67 immunostaining of intrapulmonary arteriole sections from wild-type (WT) and transgenic (TG) mice before
treatment and on days 1 and 8 posttreatment. Arrowheads indicate positively stained cells. Original magnification  20. B and C, Endothelial cell
apoptosis (as determined by the numbers of nuclei positive for cleaved caspase 3) (B) and proliferation (as determined by the numbers of nuclei
positive for Ki-67) (C) in WT and transgenic mice before and after treatment with SU5416. Data were derived from 120 random fields at 20
magnification (n  6 mice), comparing all time points. In C, cell counts were derived from only the medial and endothelial layers, to discount
perivascular inflammatory cells. Values are the mean  SEM.   P  0.05;   P  0.01;   P  0.001. D, Representative images showing
immunostaining for CD31 (red) and cleaved caspase 3 (green). Arrowheads indicate apoptotic endothelial cells, demonstrated by colocalization
(yellow). Original magnification  20. hpf  high-power field.
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examined cellular apoptosis (caspase 3 cleavage) and
proliferation (Ki-67 staining) before and on day 1, day 8,
and day 21 following SU5416 administration (Figures
5A–C). There was no apoptosis and little cell prolifera-
tion in the lungs of untreated adult WT mice, but
transgenic mice expressed Ki-67 in the previously de-
scribed perivascular infiltrates. After SU5416 adminis-
tration, apoptosis occurred on day 1 in endothelial cells
from both WT and transgenic mice and was not evident
at other time points. On day 1 posttreatment, more cells
stained for cleaved caspase 3 in the lung parenchyma of
transgenic mice compared with the lung parenchyma of
WT mice, perhaps reflecting capillary endothelial cell
apoptosis in the lungs of the transgenic mice.
No difference in proliferation within the vessels
was seen on day 1. Subsequently, proliferating endothe-
lial cells were present in the vessels of transgenic mice
(maximal on day 8), which is consistent with an exagger-
ated proliferative response to the initial apoptotic event.
Endothelial cell proliferation was most clearly seen
within the obliterative lesions of transgenic mice. These
data are congruent with those from previous studies in
Figure 6. Gene expression patterns in pulmonary arterial smooth muscle cells (PASMCs) in response to hypoxia in the TRIIk-fib mouse strain.
A, Representative images showing -galactosidase immunostaining of PASMCs and lung fibroblasts from wild-type (WT) and transgenic (TG) mice.
Original magnification  20. B, Expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR-1) mRNA in PASMCs.
Bars show the mean  SEM.   P  0.05;   P  0.01. C, Representative images showing immunostaining for VEGF ligand, VEGFR-1, and
VEGFR-2 in pulmonary arterioles. Insets, Higher-magnification views of the boxed areas. Arrowheads indicate positive staining. Original
magnification  20.
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rat models and suggested that the vessel obliteration is
attributable to apoptosis-resistant endothelial cell clones.
Colocalization of cleaved caspase 3 and CD31 confirmed
that endothelial cells were undergoing apoptosis in the
pulmonary vessel walls of transgenic mice (Figure 5D).
Taken together, our data demonstrate that endo-
thelial cell injury occurring in the context of perturbed
vascular remodeling/repair due to altered TGF signal-
ing in vascular adventitia and smooth muscle may trigger
a phenotype reminiscent of PAH. The broader pheno-
type of the TRIIk-fib mouse model and the results of
earlier studies of epithelial injury and lung fibrosis are
consistent with a central role of perturbed TGF signal-
ing in fibroblasts as a pivotal pathogenic factor in the
development of SSc-related complications, including
PAH.
Gene expression patterns in TRIIk-fib mouse
PASMCs. The altered constitutive pulmonary vascular
phenotype of the TRIIk-fib mouse strain and exag-
gerated response to VEGFR-2 inhibition in the pulmo-
nary arterial circulation led us to investigate gene ex-
pression responses in PASMCs, particularly responses to
hypoxic stress, and whether these differed from the
responses in vascular SMCs from other sites. PASMCs
were cultured in hypoxic conditions and compared with
aortic SMCs from the same mice and with PASMCs
cultured under standard conditions.
First, -galactosidase staining of PASMCs con-
firmed that they did not express the transgene (Figure
6A). More than 99% of cells expressed -SMA, with no
difference in expression or distribution between trans-
genic and WT mouse cells. Growth curves showed no
significant differences (data not shown). Key gene ex-
pression differences in the VEGF signaling axis were
present in the PASMCs from transgenic mice. Trans-
genic mouse PASMCs cultured in 21% oxygen expressed
amounts of VEGF and VEGFR-1 similar to those
expressed by WT mouse cells kept at 1% oxygen, and
up-regulation of receptors in response to 1% oxygen was
observed (Figure 6B). VEGFR-1 expression was 2-fold
higher in transgenic mouse PASMCs than in aortic
SMCs (mean  SEM copy number 6,345  836 versus
3,360  289; P  0.01), but the expression patterns in
response to 1% oxygen and TGF were similar.
Figure 6C shows representative images of immu-
nohistochemical staining for the expression of VEGF
ligand and VEGFR. VEGF ligand expression within
SMCs was up-regulated in transgenic mice. In WT mice,
VEGF expression was confined to the endothelium.
VEGFR-1 expression was present in the smooth muscle
layer and was not increased in transgenic mice.
VEGFR-2 expression was predominantly endothelial
and was increased in transgenic mice. Thus, increased
TGF activity in the pulmonary vasculature of trans-
genic mice results in up-regulated VEGF axis signaling,
but this may confer a risk of increased susceptibility to
endothelial cell apoptosis once VEGF axis signaling is
temporarily inhibited by SU5416. The higher VEGF
expression levels following inhibition in the transgenic
mice may then be responsible for the exaggerated endo-
thelial cell proliferation seen in the vessels of transgenic
mice. Of interest, when exogenous TGF was adminis-
tered to normal cultured human PASMCs, the effects on
VEGF and VEGFR-1 expression were similar to those
observed in transgenic mouse PASMCs (data not
shown). This supports the underlying role of increased
TGF activity in the transgenic mice and suggests that a
similar mechanism could apply in human PASMCs.
DISCUSSION
In this study, we have added to earlier work
evaluating a novel transgenic mouse model of sclero-
derma by defining, for the first time, the pulmonary
vascular phenotype of the TRIIk-fib mouse strain.
Our findings provide fundamental insight into potential
pathogenic mechanisms that are very relevant to human
disease and especially to the development of SSc-
associated PAH. In the TRIIk-fib mouse strain, al-
terations in TGF and VEGF signaling within the
pulmonary circulation were confirmed, together with a
structural vasculopathy reminiscent of murine chronic
hypoxic PH, with smooth muscle hypertrophy, inflam-
matory changes, and modest elevations in RV pressure.
Furthermore, experimental pulmonary endothelial cell
injury with an inhibitor of VEGF signaling induced
obliterative endothelial proliferation and remodeling of
the right ventricle. Our study provides compelling evi-
dence for the role of altered TGF signaling in pulmo-
nary vasculopathy and the importance of VEGF in
endothelial cell homeostasis. This combination of ge-
netic and pharmacologic perturbation is relevant to the
pathogenesis of human SSc-related PAH.
The TRIIk-fib mouse model has fibroblast-
specific perturbation of TGF signaling: a kinase-
deficient nonsignaling TGF receptor results in para-
doxical excessive TGF signaling and a phenotype prone
to fibrosis (17,18), with increased susceptibility to minor
lung epithelial injury (21) and a systemic vasculopathy
associated with a fibrotic left ventricular cardiomyopathy
(22). The observation that fibroblast-specific transgene
expression results in an activated phenotype in epithe-
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lium and SMCs is testament to the likelihood of by-
stander effects on other cell types and a key regulatory
and homeostatic role for resident fibroblasts. Up-
regulation of VEGF ligand and VEGFR is likely to lead
to increased VEGF axis activity in vivo, which may
underlie some of the changes in the vascular SMC layer
seen in both the transgenic mice and the WT hypoxic
mice. In this study, we demonstrate that TGF1 up-
regulates VEGF signaling in human PASMCs, which is
consistent with previous reports (24–26).
We propose that up-regulated VEGF signaling in
transgenic mice becomes a critical factor for pulmonary
endothelial cell homeostasis and survival and reflects
detrimental effects of increased TGF exposure on
vascular endothelial cells and SMCs (27). Our in vitro
experiments show up-regulated VEGF signaling in
PASMCs compared with aortic SMCs from transgenic
mice, but in vivo experiments are not directly compara-
ble with the situation in vivo, where PASMCs subsist in
an environment with lower oxygen concentrations than
those in which aortic SMCs subsist.
Similar to what occurs in the chronic hypoxia
model, increased activity of the VEGF ligand/receptor
axis may render pulmonary arterial endothelial cells
from transgenic mice more susceptible than those from
WT mice to the effects of SU5416. Paradoxically, up-
regulated VEGF signaling also leads to enhanced pro-
liferation and reduced apoptosis of endothelial cells and
underlies the exaggerated intimal and luminal changes
seen after SU5416 exposure. This severe obliterative
vascular disease is reminiscent of SSc-related PAH. A
key strength of our model is that it obviates the need for
long-term exposure to hypoxia in generating a PAH-like
pathology, although both this and the chronic hypoxia
model could be considered an extreme phenotype in
comparison with the human disease. Potential interplay
between the constitutive fibroblast-dependent up-
regulation of TGF activity, increased VEGF ligand
and receptor expression, and the impact of transient
SU5416-mediated pharmacologic inhibition of VEGFR-2
leads to the development of a PAH-like phenotype in
this transgenic mouse strain.
It is probable that changes in the vascular tree
within the lungs of patients with SSc-related PAH reflect
an aberrant fibrotic response to a vascular insult. Dys-
functional myocardial adaptive responses to pressure
overload of the right ventricle due to subclinical inflam-
matory and fibrotic myocardial disease may also contrib-
ute to the clinical picture (28,29). Furthermore, when
pulmonary fibrosis coexists, the contribution to symp-
toms and pulmonary pressure must not be understated.
At 16 weeks of age, 25% of TRIIk-fib mice develop
spontaneous mild pulmonary fibrosis, and although
younger mice were used in this study (to avoid this
confounder), the propensity for pulmonary fibrosis and
fibrotic ventricular change in this model (18,22) does
reflect this clinical situation. Thus, the investigation of
older TRIIk-fib mice would be relevant to investigate
the interplay of lung fibrosis, PAH, and fibrotic myocar-
dial disease.
When characterizing SSc-related PAH in partic-
ular, there are some important considerations. Veno-
occlusive disease has been reported more frequently in
SSc-related PAH than in idiopathic PAH (12,13), al-
though there is no evidence of venous involvement in the
TRIIk-fib mouse model. The relative role of inflam-
mation in the pathogenesis of SSc-related PAH when
compared with idiopathic PAH is also relevant. There is
perivascular inflammation in both idiopathic PAH and
SSc-related PAH, and detailed characterization of these
inflammatory infiltrates in patients with idiopathic PAH
was recently described (30). Gene expression analyses
have identified inflammatory signatures in both idio-
pathic PAH and SSc-related PAH (31). SSc-related
PAH has been labeled a prototypic inflammatory dis-
ease due to the autoantibody associations and identifi-
cation of early inflammatory cell recruitment (7), but the
precise role of inflammation in the pathogenesis of
either condition remains unclear.
The contribution of endothelial cells to the
pathogenesis of PAH is uncertain but highly relevant to
this study. Data supporting a role for endothelial cell
perturbation in SSc-associated vasculopathy and PAH
in vivo are available from several studies, but informa-
tion regarding direct functional mechanisms is lacking.
It is likely that healthy endothelial cells interact with
SMCs and fibroblasts for vessel homeostasis, and it is
plausible that VEGF-mediated pathways modulate en-
dothelial cell responses to hypoxia.
Both vascular pathology and fibrosis have been
described in genetic mouse models of SSc. Caveolin
1–knockout mice were shown to have high TGF bio-
activity, with abnormal endothelial function and in-
creased RV pressure without the cardinal features of
PAH (32). The Fra-2–transgenic mouse strain has al-
tered activated protein 1 signaling and severe fibrosis of
the lung and kidney, resulting in early mortality. Ubiq-
uitous transgene expression and an inability to distin-
guish endogenous from transgenic expression of Fra-2
complicate analysis of the mechanism of fibrosis and
vasculopathy, although the model has clear relevance to
cases of SSc in which lung fibrosis and PH coexist (33)
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and a predominant fibrotic phenotype. A major strength
of the present study is the use of a model that clearly
reflects the likely pathogenetic mechanism underlying
SSc-associated vascular disease and the potential to
aggravate the phenotype with a relevant trigger. Aber-
rant TGF signaling is widely recognized to be related to
SSc pathogenesis, and this model provides a plausible
mechanism for the secondary alterations in related
signaling pathways resulting in the development of vas-
culopathy.
In conclusion, in this study we replicated features
of human SSc-related PAH in a relevant transgenic
mouse model and defined likely pathogenic mechanisms
underlying this novel phenotype. Thus, we suggest a
paradigm in which a background TGF-dependent pul-
monary vasculopathy renders mice susceptible to endo-
thelial cell proliferation after injury, leading to hallmark
features of SSc-related PAH. In addition to providing
mechanistic insights, this model also provides a platform
for preclinical interventional studies of this important
complication of SSc and for exploration of potential
treatment strategies that attenuate other mediators or
signaling pathways that might be regulated by TGF or
VEGF.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Dr. Denton had full access to all of
the data in the study and takes responsibility for the integrity of the
data and the accuracy of the data analysis.
Study conception and design. Derrett-Smith, Khan, Baliga, Holmes,
Abraham, Denton.
Acquisition of data. Derrett-Smith, Dooley, Gilbane, Trinder, Khan,
Baliga, Hobbs, Denton.
Analysis and interpretation of data. Derrett-Smith, Khan, Baliga,
Abraham, Denton.
REFERENCES
1. Hachulla E, Coghlan JG. A new era in the management of
pulmonary arterial hypertension related to scleroderma: endothe-
lin receptor antagonism [review]. Ann Rheum Dis 2004;63:
1009–14.
2. Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P,
et al. Prevalence of pulmonary hypertension in systemic sclerosis
in European Caucasians and meta-analysis of 5 studies. J Rheu-
matol 2010; 37:2290–8.
3. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-
Harris T, Hummers L, et al. Clinical differences between idio-
pathic and scleroderma-related pulmonary hypertension. Arthritis
Rheum 2006;54:3043–50.
4. Tan FK. Systemic sclerosis: the susceptible host (genetics and
environment) [review]. Rheum Dis Clin North Am 2003;29:
211–37.
5. Jonigk D, Golpon H, Bockmeyer CL, Maegel L, Hoeper MM,
Gottlieb J, et al. Plexiform lesions in pulmonary arterial hyperten-
sion: composition, architecture, and microenvironment. Am J
Pathol 2011;179:167–79.
6. Al Sabbagh MR, Steen VD, Zee BC, Nalesnik M, Trostle DC,
Bedetti CD, et al. Pulmonary arterial histology and morphometry
in systemic sclerosis: a case-control autopsy study. J Rheumatol
1989;16:1038–42.
7. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC,
Grimminger F, et al. Inflammation, growth factors and pulmonary
vascular remodeling. J Am Coll Cardiol 2009;54:S10–9.
8. Okawa-Takatsuji M, Aotsuka S, Fujinami M, Uwatoko S, Ki-
noshita M, Sumiya M. Up-regulation of intercellular adhesion
molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1
(ELAM-1) and class II MHC molecules on pulmonary artery
endothelial cells by antibodies against U1-ribonucleoprotein. Clin
Exp Immunol 1999;116:174–80.
9. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder
RM. Monoclonal endothelial cell proliferation is present in pri-
mary but not secondary pulmonary hypertension. J Clin Invest
1998;101:927–34.
10. Choi JJ, Min DJ, Cho ML, Min SY, Kim SJ, Lee SS, et al. Elevated
vascular endothelial growth factor in systemic sclerosis. J Rheu-
matol 2003;30:1529–33.
11. Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML,
Guiducci S, et al. Angiogenic and angiostatic factors in systemic
sclerosis: increased levels of vascular endothelial growth factor are
a feature of the earliest disease stages and are associated with the
absence of fingertip ulcers. Arthritis Res 2002;4:R11.
12. Dorfmuller P, Humbert M, Perros F, Sanchez O, Simonneau G,
Muller KM, et al. Fibrous remodeling of the pulmonary venous
system in pulmonary arterial hypertension associated with connec-
tive tissue diseases. Hum Pathol 2007;38:893–902.
13. Overbeek MJ, Vonk MC, Boonstra A, Voskuyl AE, Vonk-Noor-
degraaf A, Smit EF, et al. Pulmonary arterial hypertension in
limited cutaneous systemic sclerosis: a distinctive vasculopathy.
Eur Respir J 2009;34:371–9.
14. Tew MB, Arnett FC, Reveille JD, Tan FK. Mutations of bone
morphogenetic protein receptor type II are not found in patients
with pulmonary hypertension and underlying connective tissue
diseases [letter]. Arthritis Rheum 2002;46:2829–30.
15. Wipff J, Kahan A, Hachulla E, Sibilia J, Cabane J, Meyer O, et al.
Association between an endoglin gene polymorphism and systemic
sclerosis-related pulmonary arterial hypertension. Rheumatology
(Oxford) 2007;46:622–5.
16. Wipff J, Dieude P, Guedj M, Ruiz B, Riemekasten G, Cracowski
JL, et al. Association of a KCNA5 gene polymorphism with
systemic sclerosis–associated pulmonary arterial hypertension in
the European Caucasian population. Arthritis Rheum 2010;62:
3093–100.
17. Denton CP, Zheng B, Evans LA, Shi-wen X, Ong VH, Fisher I, et
al. Fibroblast-specific expression of a kinase-deficient type II
transforming growth factor  receptor leads to paradoxical activa-
tion of TGF  signaling pathways with fibrosis in transgenic mice.
J Biol Chem 2003;278:25109–19.
18. Denton CP, Lindahl GE, Khan K, Shiwen X, Ong VH, Gaspar NJ,
et al. Activation of key profibrotic mechanisms in transgenic
fibroblasts expressing kinase-deficient type II transforming growth
factor- receptor (TRIIk). J Biol Chem 2005;280:16053–65.
19. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, McMahon
G, Waltenberger J, et al. Inhibition of the VEGF receptor 2
combined with chronic hypoxia causes cell death-dependent pul-
monary endothelial cell proliferation and severe pulmonary hy-
pertension. FASEB J 2001;15:427–38.
20. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good
R, et al. A novel murine model of severe pulmonary arterial
hypertension. Am J Respir Crit Care Med 2011;184:1171–82.
21. Hoyles RK, Khan K, Shiwen X, Howat SL, Lindahl GE, Leoni P,
et al. Fibroblast-specific perturbation of transforming growth
2938 DERRETT-SMITH ET AL
factor  signaling provides insight into potential pathogenic mech-
anisms of scleroderma-associated lung fibrosis: exaggerated re-
sponse to alveolar epithelial injury in a novel mouse model.
Arthritis Rheum 2008;58:1175–88.
22. Derrett-Smith EC, Dooley A, Khan K, Shi-wen X, Abraham D,
Denton CP. Systemic vasculopathy with altered vasoreactivity in a
transgenic mouse model of scleroderma. Arthritis Res Ther 2010;
12:R69.
23. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De
Paepe A, et al. Accurate normalization of real-time quantitative
RT-PCR data by geometric averaging of multiple internal control
genes. Genome Biology 2002;3:1–11.
24. Tanabe K, Tokuda H, Takai S, Matsushima-Nishiwaki R, Hanai Y,
Hirade K, et al. Modulation by the steroid/thyroid hormone
superfamily of TGF--stimulated VEGF release from vascular
smooth muscle cells. J Cell Biochem 2006;99:187–95.
25. Mata-Greenwood E, Grobe A, Kumar S, Noskina Y, Black SM.
Cyclic stretch increases VEGF expression in pulmonary arterial
smooth muscle cells via TGF-1 and reactive oxygen species: a
requirement for NAD(P)H oxidase. Am J Physiol Lung Cell Mol
Physiol 2005;289:L288–98.
26. Kobayashi T, Liu X, Wen FQ, Fang Q, Abe S, Wang XQ, et al.
Smad3 mediates TGF-1 induction of VEGF production in lung
fibroblasts. Biochem Biophys Res Commun 2005;327:393–8.
27. Ferrari G, Terushkin V, Wolff MJ, Zhang X, Valacca C, Poggio P,
et al. TGF-1 induces endothelial cell apoptosis by shifting VEGF
activation of p38MAPK from the prosurvival p38 to proapoptotic
p38. Mol Cancer Res 2012;10:605–14.
28. Fernandes F, Ramires FJ, Arteaga E, Ianni BM, Bonfa ES, Mady
C. Cardiac remodeling in patients with systemic sclerosis with no
signs or symptoms of heart failure: an endomyocardial biopsy
study. J Card Fail 2003;9:311–7.
29. Overbeek MJ, Lankhaar JW, Westerhof N, Voskuyl AE, Boonstra
A, Bronzwaer JG, et al. Right ventricular contractility in systemic
sclerosis-associated and idiopathic pulmonary arterial hyperten-
sion. Eur Respir J 2008;31:1160–6.
30. Grigoryev DN, Mathai SC, Fisher MR, Girgis RE, Zaiman AL,
Housten-Harris T, et al. Identification of candidate genes in
scleroderma-related pulmonary arterial hypertension. Transl Res
2008;151:197–207.
31. Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L,
et al. Immune and inflammatory cell involvement in the pathology
of idiopathic pulmonary arterial hypertension. Am J Respir Crit
Care Med 2012;186:897–90.
32. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL,
Marks CB, et al. Caveolin-1 null mice are viable but show evidence
of hyperproliferative and vascular abnormalities. J Biol Chem
2001;276:38121–38.
33. Maurer B, Reich N, Juengel A, Kriegsmann J, Gay RE, Schett G,
et al. Fra-2 transgenic mice as a novel model of pulmonary
hypertension associated with systemic sclerosis. Ann Rheum Dis
2012;71:1382–7.
PAH IN A MOUSE MODEL OF SCLERODERMA 2939
